Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 7/20 | 0.81 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.81 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.81 |
| ▸ | CDK2 | P24941 | 3/20 | 0.81 |
| ▸ | NPC1 | O15118 | 2/20 | 0.81 |
| ▸ | MAPT | P10636 | 2/20 | 0.81 |
| ▸ | XBP1 | P17861 | 2/20 | 0.81 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.81 |
| ▸ | HTT | P42858 | 2/20 | 0.81 |
| ▸ | RAB9A | P51151 | 2/20 | 0.81 |
| ▸ | CDK4 | P11802 | 2/20 | 0.81 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.81 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.81 |
| ▸ | CCND1 | P24385 | 2/20 | 0.81 |
| ▸ | CDK7 | P50613 | 2/20 | 0.81 |
| ▸ | CCNH | P51946 | 2/20 | 0.81 |
| ▸ | MTOR | P42345 | 2/20 | 0.81 |
| ▸ | SMG1 | Q96Q15 | 2/20 | 0.81 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.81 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30782585 | 0.89 | CDK1 (1.00) | CDK1CDK5CDK5R1CDK2NPC1 | |
| SCHEMBL29397852 | 0.89 | CDK1 (1.00) | CDK1CDK5CDK5R1CDK2NPC1 | |
| SCHEMBL1574530 | 0.89 | CDK1 (1.00) | CDK1CDK5CDK5R1CDK2NPC1 | |
| SCHEMBL29385808 | 0.89 | CDK1 (1.00) | CDK1CDK5CDK5R1CDK2NPC1 | |
| SCHEMBL7813303 | 0.87 | CDK1 (0.96) | CDK1CDK5CDK5R1CDK2NPC1 | |
| SCHEMBL7804352 | 0.86 | CDK1 (0.94) | CDK1CDK5CDK5R1CDK2NPC1 | |
| SCHEMBL4897568 | 0.85 | CDK1 (0.78) | CDK1CDK5CDK5R1CDK2NPC1 | |
| SCHEMBL14040966 | 0.85 | CDK1 (0.85) | CDK1CDK5CDK5R1CDK2NPC1 | |
| SCHEMBL7817083 | 0.85 | CDK1 (0.91) | CDK1CDK5CDK5R1CDK2NPC1 | |
| SCHEMBL3511867 | 0.83 | CDK1 (0.72) | CDK1CDK5CDK5R1CDK2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160024497-A1 | Compositions And Methods For Inhibiting Expression Of GSK-3 Genes | ALNYLAM PHARMACEUTICALS, INC. | 2016-01-28 | — | — | US | disclosed |
| US-20160024497-A1 | Compositions And Methods For Inhibiting Expression Of GSK-3 Genes | ALNYLAM PHARMACEUTICALS, INC. | 2016-01-28 | — | — | US | disclosed |
| US-9029525-B2 | Compositions and methods for inhibiting expression of GSK-3 genes | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029525-B2 | Compositions and methods for inhibiting expression of GSK-3 genes | ALNYLAM PHARMACEUTICALS, INC. (US) | 2015-05-12 | — | — | US | disclosed |
| US-20130012572-A1 | Compositions And Methods For Inhibiting Expression Of GSK-3 Genes | BANK OF AMERICA, N.A. | 2013-01-10 | — | — | US | disclosed |
| US-20130012572-A1 | Compositions And Methods For Inhibiting Expression Of GSK-3 Genes | BANK OF AMERICA, N.A. | 2013-01-10 | — | — | US | disclosed |
| US-20120009674-A1 | Use of a GSK-3 Inhibitor to Maintain Potency of Cultured Cells | ABT HOLDING COMPANY (US) | 2012-01-12 | — | — | US | disclosed |
| US-20110184046-A1 | Compositions And Methods For Inhibiting Expression Of GSK-3 Genes | ALNYLAM PHARMACEUTICALS, INC. | 2011-07-28 | — | — | US | disclosed |
| US-20110184046-A1 | Compositions And Methods For Inhibiting Expression Of GSK-3 Genes | ALNYLAM PHARMACEUTICALS, INC. | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012572-A1 | Compositions And Methods For Inhibiting Expression Of GSK-3 Genes | GSK3A, GSK3B, GSKIP | CDK1 1035/4885CDK5 782/4885CDK5R1 1119/4885 |
| US-20110184046-A1 | Compositions And Methods For Inhibiting Expression Of GSK-3 Genes | GSK3A, GSK3B, GSKIP | CDK1 1035/4885CDK5 782/4885CDK5R1 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.